Please login to the form below

Not currently logged in
Email:
Password:

monalizumab

This page shows the latest monalizumab news and features for those working in and with pharma, biotech and healthcare.

Innate Pharma and AstraZeneca take monalizumab into phase 3

Innate Pharma and AstraZeneca take monalizumab into phase 3

Innate Pharma’s lead candidate monalizumab – which is licensed by AstraZeneca – is heading for a pivotal phase 3 clinical trial. . ... The biotech – based in Marseille, France – will proceed into a phase 3 trial evaluating monalizumab in

Latest news

  • France’s Innate Pharma eyes $100m Nasdaq IPO France’s Innate Pharma eyes $100m Nasdaq IPO

    Some of the proceeds will go towards Innate’s lead candidate monalizumab, an anti-NKG2A antibody which was  licensed by AstraZeneca last year in a deal that included $100m in ... The French biotech licensed co-commercial rights to the drug at the same

  • AZ invests more in IO with Transgene oncolytic virus deal AZ invests more in IO with Transgene oncolytic virus deal

    It signed a deal with France’s Innate Pharma last October (centred on its anti-NKG2A antibody, monalizumab (IPH2201), and yesterday added an alliance with another French biotech, Transgene.

  • AZ swells immuno-oncology pipeline with Innate deal AZ swells immuno-oncology pipeline with Innate deal

    The main subject of the deal is Innate’s anti-NKG2A antibody, monalizumab (IPH2201), which targets a pathway thought to inhibit the activity of natural killer (NK) and cytotoxic T-cells ... for an option on anti-CD39 candidate IPH5201, which is in

  • Bad news for Innate Pharma as BMS-backed drug stumbles Bad news for Innate Pharma as BMS-backed drug stumbles

    Innate is also developing another checkpoint inhibitor - a CD94/NKG2A targeting antibody called monalizumab - as a monotherapy and in combination with AZ’s recently-approved PD-L1 inhibitor Imfinzi (durvalumab).

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    AstraZeneca. Anti-NKG2A antibody (monalizumab), IPH5201 (antibody targeting CD38) and Lumoxiti. #. for hairy cell leukaemia. Development &. commercialisation. collaboration. $307m. ViraTherapeutics/. Boehringer Ingelheim.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics